VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LFMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LFMDLifeMD, Inc.
$1.85$89M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LFMD
  4. Financial Ratios

LifeMD, Inc. (LFMD) Financial Ratios

Latest Ratios: P/E Ratio -4.1x · EV/EBITDA N/A · ROE -74.4%. (2011–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LFMD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$89M$154M$204M$281M$60M$105M$93M$6M$6M$15M$9M
Enterprise Value$59M$123M$194M$267M$60M$65M$85M$6M$6M$15M$9M
P/E Ratio →-4.07——————————
P/S Ratio0.470.790.961.840.501.132.500.480.762.961.75
P/B Ratio3.616.65—50.50—4.05——7.7324.01—
P/FCF——34.123232.66———23.62———
P/OCF10.8118.5911.6431.87———23.62———

P/E links to full P/E history page with 30-year chart

LFMD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—0.640.911.750.510.702.280.460.772.961.75
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF——32.463069.18———22.58———

LFMD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin79.8%79.8%88.7%87.6%84.3%80.6%76.2%79.7%76.3%70.6%62.9%
Operating Margin-4.0%-4.0%-7.6%-9.5%-36.5%-58.5%-155.0%-23.2%-24.7%-21.1%-22.4%
Net Profit Margin-3.7%-3.7%-8.9%-13.5%-38.3%-65.6%-157.3%-25.2%-14.9%-23.9%-21.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-74.4%-74.4%-2483.1%-370.0%-491.9%-487.2%——-172.0%-923.7%—
ROA-9.9%-9.9%-28.8%-49.0%-120.5%-192.3%-696.1%-103.5%-64.0%-117.4%-178.9%
ROIC————————-200.8%-514.9%—
ROCE-37.4%-37.4%-89.9%-161.1%-406.3%-408.8%—-646.1%-200.9%-817.7%—

LFMD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.270.27—3.40—0.07——0.300.27—
Debt / EBITDA———————————
Net Debt / Equity—-1.32—-2.55—-1.53——0.080.04—
Net Debt / EBITDA———————————
Debt / FCF——-1.66-163.48———-1.04———
Interest Coverage-6.48-6.48-7.40-5.71-31.10-19.31-34.67-3.80-5.80-12.72-24.16

Net cash position: cash ($37M) exceeds total debt ($6M)

LFMD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.251.250.811.220.361.970.890.691.351.970.69
Quick Ratio1.181.180.761.150.241.900.800.450.490.870.55
Cash Ratio0.880.880.580.950.131.810.660.280.150.220.16
Asset Turnover—2.762.932.614.641.862.783.623.184.006.63
Inventory Turnover14.1714.178.606.855.0411.137.012.661.932.1012.14
Days Sales Outstanding—17.5014.1212.638.693.859.772.854.349.2631.14

LFMD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield3.7%2.0%1.5%1.1%5.2%0.8%1.4%————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield——2.9%0.0%———4.2%———
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.5%0.9%
Total Shareholder Yield3.7%2.0%1.5%1.1%5.2%0.8%1.4%0.0%0.0%0.5%0.9%
Shares Outstanding—$45M$41M$34M$31M$27M$14M$10M$9M$9M$7M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Shrinking Equity and Cash Erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Negative Earnings Leave P/E Unusable

Based on LifeMD's reported trailing figures, the P/E of -10.30 is not meaningful, while the 0.59 P/S and 4.62 P/B suggest the market still prices the equity above its book value despite shrinking revenue and losses.

With trailing earnings negative and no forward P/E available, investors cannot anchor value on earnings multiples and must rely on sales and book value instead. The 4.62 price-to-book ratio appears rich for a company whose equity fell from $23.2M to $8.0M over two quarters and whose revenue declined for consecutive periods. Compared with the peer set, where DOCS trades at 33.17x earnings and 6.81x book, LFMD's low sales multiple reflects weak growth expectations rather than a clear discount, and this gap warrants further investigation.

Gross Margin Strength Obscured by SG&A

As reported in the financial statements, LifeMD's gross margin reached 88.8% in 2026Q2, yet operating margin stayed at -15.1% because SG&A consumed nearly all gross profit.

The high gross margin indicates strong unit economics at the product level, but it does not translate into earning power because operating expenses absorb roughly 99% of gross profit. Operating margin deteriorated from +3.9% in 2025Q1 to -15.1% in 2026Q2, suggesting that cost structure is not scaling down with the revenue decline. Net margin tracks the operating trend closely, so investors should treat the gross margin as an upper bound rather than a proxy for true earnings power.

Returns Decaying as Equity Erodes

Based on LifeMD's reported figures, ROE fell to -61.6% in 2026Q2 from -11.3% a year earlier, while ROA reached -10.9%, indicating that losses are compounding against a shrinking equity base.

The steep decline in ROE is driven partly by the denominator, as equity fell from $23.2M to $8.0M, which mechanically magnifies negative returns. ROIC is not reported for any period, so the capital efficiency picture must be inferred from ROA and ROE, both of which point to value destruction. Peer NUVB shows a similarly negative ROE of -49.7%, but DOCS earns 17.0% ROE, underscoring that LFMD's return profile is structurally weak rather than cyclically depressed.

Current Ratio Slips Below Parity

According to reported financial statements, LifeMD's current ratio fell from 1.25 in 2025Q4 to 0.90 in 2026Q2, with quick ratio at 0.84, placing current liabilities above current assets.

A current ratio below 1.0 combined with a quick ratio of 0.84 suggests limited near-term coverage of short-term obligations without relying on inventory or operating inflows. Cash declined from $36.8M to $25.1M over two quarters, which compresses the liquidity buffer while operating cash flow turned negative. Under a severe stress scenario, the company's ability to meet current liabilities would depend on how quickly receivables convert, a point investors should monitor closely.

Working Capital Metrics Mislead on Cash Cycle

Based on LifeMD's reported figures, the cash conversion cycle of -269 days is driven by DPO of 343 days, which may overstate supplier financing as a source of strength.

A negative cash conversion cycle is usually read as efficiency, but here it reflects an unusually long payables period rather than fast collections, since DSO is only 21 days. Stretching payables to 343 days may indicate reliance on supplier credit that could reverse if vendors tighten terms. Investors should instead examine payables trends alongside operating cash flow, which swung from $8.6M to negative $6.9M, to judge whether the working capital benefit is durable.

Download Financial Ratios Data

Includes 30+ ratios · 15 years · Updated daily

Consensus & Technical Research Suite
Open LFMD Terminal

LFMD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LFMD — Frequently Asked Questions

Quick answers to the most common questions about buying LFMD stock.

What is LifeMD, Inc.'s P/E ratio?

LifeMD, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.

What is LifeMD, Inc.'s ROE?

LifeMD, Inc.'s return on equity (ROE) is -74.4%. The historical average is -298.4%.

Is LFMD stock overvalued?

Based on historical data, LifeMD, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is LifeMD, Inc.'s dividend yield?

LifeMD, Inc.'s current dividend yield is 3.72%.

What are LifeMD, Inc.'s profit margins?

LifeMD, Inc. has 79.8% gross margin and -4.0% operating margin.